Skip to content
Research/Longevity Anti Aging/Niagen (Nicotinamide Riboside)

Niagen (Nicotinamide Riboside)

NAD+ precursor that converts to NMN then NAD+. Clinically shown to increase NAD+ levels by ~60% in humans. Reduces arterial stiffness, neuroprotective. Brand name: Tru Niagen.

Intelligence Profile

Research Papers

Research Papers and Clinical Trials

The research on nicotinamide riboside (Niagen) shows emerging evidence across several therapeutic areas, though most studies are still in early stages.

Preclinical Research

Recent laboratory studies suggest potential benefits for neurological and muscular conditions. Research published in 2026 indicates that nicotinamide riboside may reduce inflammation in brain support cells (glial cells) and improve mitochondrial function - the cellular powerhouses responsible for energy production. Another 2026 study found it may help prevent mitochondrial problems in a rare muscle disorder called nemaline myopathy type 6.

Additional preclinical work has explored nicotinamide riboside's role in inflammatory skin conditions like psoriasis, where it appears to work through specific cellular signaling pathways to reduce inflammation. Researchers have also developed methods to track how the compound affects NAD+ levels in the liver using specialized detection techniques.

Clinical Trials

Several clinical trials have been completed or are ongoing:

  • Heart failure study (NCT03423342): A combined Phase 1/Phase 2 trial examining nicotinamide riboside in patients with systolic heart failure has been completed, though results details were not provided in the available evidence.

  • Metabolic health research (NCT02835664): A completed study investigated the compound's effects on metabolic health parameters.

  • Exercise studies (NCT04907110 and NCT03432871): Completed trials have examined nicotinamide riboside supplementation in combination with exercise and its effects on mitochondrial function.

  • Injectable formulation (NCT06919328): An ongoing study is comparing injectable Niagen+ to NAD+ in terms of absorption and tolerability.

Study Limitations

The available evidence shows sample sizes and detailed methodology were not provided for most studies. While the research suggests potential therapeutic applications, particularly for mitochondrial function and inflammation, more robust clinical data with larger patient populations and longer follow-up periods would be needed to establish clear therapeutic benefits.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any supplement regimen.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.